Resurgence of influenza and respiratory syncytial virus in Egypt following two years of decline during the COVID-19 pandemic: outpatient clinic survey of infants and children, October 2022.
Acute respiratory infection
Influenza viruses
Outbreak
Respiratory Syncytial virus
Survey
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
05 06 2023
05 06 2023
Historique:
received:
20
02
2023
accepted:
11
05
2023
medline:
7
6
2023
pubmed:
6
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Two years after unprecedented low rates of circulation of most common respiratory viruses (SARS-CoV-2), the Egyptian ARI surveillance system detected an increase in acute respiratory infections (ARIs) with a reduced circulation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially among school children. A national survey was conducted to estimate the burden and identify the viral causes of ARIs among children < 16 years of age. A one-day survey was carried out in 98 governmental outpatient clinics distributed all over Egypt 26 governorates. The four largest referral hospitals in each governorate where most influenza-like illness (ILI) patients seek care were selected. Using the WHO case definition, the first five patients < 16 years of age with ILI symptoms visiting the selected outpatient clinics on the survey day were enrolled. Basic demographic and clinical data of patients were collected using a linelist. Patients were swabbed and tested for SARS-CoV-2, influenza, and Respiratory Syncytial virus (RSV) by RT-PCR at the Central Laboratory in Cairo. Overall, 530 patients enrolled, their mean age was 5.8 ± 4.2, 57.1% were males, and 70.2% reside in rural or semi-rural areas. Of all patients, 134 (25.3%) had influenza, 111 (20.9%) RSV, and 14 (2.8%) coinfections. Influenza-positive children were older compared to RSV, (7.2 ± 4.1, 4.3 ± 4.1, p < 0.001), with more than half of them (53.0%) being school students. Dyspnea was reported in RSV more than in influenza (62.2% vs. 49.3%, p < 0.05). Among RSV patients, children < 2 years had a higher rate of dyspnea than others (86.7% vs. 53.1%, < 0.001). A resurgence of influenza and RSV was detected in Egypt in the 2022-2023 winter season. Influenza caused a higher rate of infection than RSV, while RSV caused more severe symptoms than influenza. Monitoring a broader range of respiratory pathogens is recommended to estimate the ARI burden and risky groups for severe disease in Egypt.
Identifiants
pubmed: 37277781
doi: 10.1186/s12889-023-15880-9
pii: 10.1186/s12889-023-15880-9
pmc: PMC10240446
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067Informations de copyright
© 2023. The Author(s).
Références
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296675
Front Immunol. 2014 Sep 29;5:466
pubmed: 25324843
JAMA Netw Open. 2022 Feb 01;5(2):e220527
pubmed: 35226079
Lancet Infect Dis. 2023 Jan;23(1):56-66
pubmed: 36063828
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296674
BMC Public Health. 2008 Feb 14;8:61
pubmed: 18275603
Am J Epidemiol. 2011 Jul 1;174(1):109-17
pubmed: 21602300
Epidemics. 2022 Sep;40:100614
pubmed: 35901639
Immunol Allergy Clin North Am. 2019 Aug;39(3):361-376
pubmed: 31284926
Pediatrics. 2009 Dec;124(6):e1072-80
pubmed: 19933730
BMJ Open. 2022 Dec 19;12(12):e060805
pubmed: 36535718
MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):913-919
pubmed: 35862284
PLoS One. 2021 Jun 18;16(6):e0253451
pubmed: 34143839
J Infect Dis. 2013 Dec 15;208 Suppl 3:S189-96
pubmed: 24265478
Emerg Infect Dis. 2021;27(7):1821-1830
pubmed: 34152951
Influenza Other Respir Viruses. 2021 Sep;15(5):589-598
pubmed: 33960675
Emerg Infect Dis. 2022 Feb;28(2):273-281
pubmed: 35075991
Nat Rev Microbiol. 2023 Mar;21(3):195-210
pubmed: 36253478
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243355
Pediatr Pulmonol. 2014 May;49(5):430-4
pubmed: 24610581
Influenza Other Respir Viruses. 2019 Jul;13(4):339-353
pubmed: 30891896
MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-1019
pubmed: 34292924
Vaccine. 2008 Sep 12;26 Suppl 4:D49-53
pubmed: 19230160
Can J Infect Dis Med Microbiol. 2022 Nov 17;2022:7497500
pubmed: 36437892
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Clin Infect Dis. 2021 Jun 15;72(12):2199-2202
pubmed: 32986804
Public Health Pract (Oxf). 2023 Jun;5:100358
pubmed: 36686982
Nature. 2022 Dec 15;:
pubmed: 36522537
Vaccine. 2008 Dec 9;26(52):6818-23
pubmed: 18940222
Scand J Infect Dis. 2004;36(1):31-6
pubmed: 15000556
Pediatr Pulmonol. 2022 Jan;57(1):38-42
pubmed: 34644459
J Glob Health. 2021 Mar 01;11:05007
pubmed: 33791096
Vaccine. 2011 Oct 6;29(43):7524-8
pubmed: 21820476
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
Eur J Pediatr. 2004 Jul;163(7):359-63
pubmed: 15106003
Infection. 2019 Aug;47(4):595-601
pubmed: 30798473
J Korean Med Sci. 2021 Dec 13;36(48):e328
pubmed: 34904407
Clin Microbiol Rev. 2008 Oct;21(4):716-47
pubmed: 18854489
Nat Commun. 2022 Mar 31;13(1):1721
pubmed: 35361789
Pediatr Pulmonol. 2021 Dec;56(12):3669-3673
pubmed: 34473914
Virol J. 2015 Dec 12;12:215
pubmed: 26651485
BMC Pediatr. 2021 Apr 22;21(1):195
pubmed: 33888063